Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimizing NPC Screening with EBV DNA and P85-Ab
NCT06870435Recruiting
- Start
- Jan 2025
- Primary completion
- Jan 2026
- Countries
- 1
01
Overview
Open-label, single-arm trial. Primary endpoints: Sensitivity of EBV DNA, P85-Ab, and two-antibody method at 10 years, Specificity of EBV DNA, P85-Ab, and two-antibody method at 10 years and 1 more. Started Jan 2025; status: recruiting.
Beyond the preview
Go deeper on NCT06870435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06870435.